CPX-351
CLTR0310-301
Phase 3 small_molecule completed
Quick answer
CPX-351 for High Risk Acute Myeloid Leukemia is a Phase 3 program (small_molecule) at Jazz Pharmaceuticals plc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Jazz Pharmaceuticals plc
- Indication
- High Risk Acute Myeloid Leukemia
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed